拉米夫定
- 名Lamivudine
-
拉米夫定对乙型肝炎病毒DNA复制及基因变异的影响
Effects of lamivudine on DNA duplication and genetic mutation of hepatitis B
-
基因芯片技术检测HBVdna及拉米夫定耐药株的应用研究
Application Study of Genechip Detecting HBV DNA and Lamivudine Resistant Mutants
-
拉米夫定治疗前后乙型肝炎病毒P区基因的动态变化
Dynamic variations of hepatitis B virus polymerase gene in lamivudine-treated hepatitis B patients
-
结论拉米夫定能强烈抑制HBVdna的复制。
Conclusion HBV DNA loss could be obtained by lamivudine therapy .
-
拉米夫定抑制乙型肝炎病毒X基因的转录与表达
Inhibition of transcription and expression of X gene by lamivudine
-
观察拉米夫定治疗过程中,血清HBVdna水平的变化。
To detect the variety of seral HBV DNA level during lamivudine therapy .
-
拉米夫定对慢性乙肝患者HBVdna的阴转作用
Negative conversion effect of lamivudine on HBV DNA in patients with chronic HBV hepatitis
-
拉米夫定对肺结核并HBV感染患者的作用分析
Efficacy of Lamivudine for Pulmonary Tuberculosis Complicated with Hepatitis B Virus Infection
-
拉米夫定联合干扰素治疗慢性HBV感染的临床研究
Clinical Study of Lamivudine and Interferon Combination Therapy for Chronic Hepatitis B Infection
-
拉米夫定与α-干扰素不同用药方式抗HBV疗效分析
Effect of lamivudine and interferon - α treatment in different way on HBV infection
-
拉米夫定相关性HBV变异对乙型肝炎预后的影响
Influence of HBV mutation during lamivudine treatment on clinical prognosis of chronic hepatitis B
-
单用拉米夫定治疗慢性HBV感染期间发生暴发性肝炎的预测指标
Prognostic indicators of breakthrough hepatitis during lamivudine monotherapy for chronic hepatitis B virus infection
-
【目的】研究拉米夫定对HBsAg阳性孕妇的乙肝病毒(HBV)宫内阻断作用。
To study the interruptive effect of Lamivudine in HBsAg positive pregnant women .
-
慢性HBV感染者辅助性T细胞功能分析及拉米夫定治疗对其影响
Chronic HBV Infection : Analysis of T Helper Cells Function and Influence of Lamivudine Therapy
-
结论拉米夫定联合肌肉注射剂型的人乙型肝炎免疫球蛋白可有效预防肝移植术后HBV再感染;
Conclusions Combination of intramuscular HBIg and Lamivudine as prophylaxis of HBV reinfection is effective .
-
目的:探讨甘草酸二铵治疗拉米夫定致HBV变异后的肝功能异常的疗效。
Objective : To observe diammonium glycyrrhizinate for impaired liver function due to lamivudine-induced HBV mutation .
-
预防性短期使用拉米夫定预防HBV再激活是有效及安全的。
It is effective and safe that preventing HBV reactivation by lamivudine in a short term .
-
慢性HBV感染者的T细胞亚群与拉米夫定临床疗效的关系
The correlation between T-lymphocyte subsets and clinical efficacy of lamivudine in patients with chronic hepatitis B
-
甘草酸二铵治疗拉米夫定致HBV变异后的肝功能异常
Effects of diammonium glycyrrhizinate on impaired liver function associated with hepatitis B virus mutation to lamivudine
-
【结论】拉米夫定对HBV标志物阳性的肾病综合征患者激素治疗过程中的HBV复制有防治作用。
【 Conclusion 】 Lamivudine can play a preventive role in nephritic syndrome with HBV infection .
-
方法共66例拉米夫定耐药患者,分治疗组A、治疗组B和对照组。
Methods Sixty six patients with CHB resistant to lamivudine were enrolled and randomized into treatment group A , treatment group B and control group .
-
目的:研究基因芯片技术检测HBVdna及拉米夫定耐药株在临床应用中的特异性、实用性。
Objective : To study the specificity and practicability of genechip detecting HBV DNA and lamivudine resistant mutants in clinic .
-
HBV耐拉米夫定多聚酶基因变异检测方法的建立
Establishment of a method for the detection of lamivudine-resistant mutants in the sequence of HBV polymerase gene
-
山东地区HBV基因型分布及拉米夫定抗病毒治疗对基因分型的影响
Distribution of HBV genotypes in Shandong province and it 's relationship with the antiviral effect of lamivudine
-
拉米夫定起始的核苷酸类似物对e抗原阴性的慢性乙型肝炎长期治疗
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos ( t ) ide analog therapy starting with lamivudine
-
结论拉米夫定不仅抑制HBVdna复制效果理想,而且间接阻断肝纤维化的形成十分显效。
Conclusion Not only did Lamivudine effectively inhibit replication of HBV DNA , but also indirectly impeded formation of liver fibrosis .
-
拉米夫定和大剂量干扰素-α联合治疗未经治疗的慢性HBV感染患儿
Lamivudine and high - dose interferon - α combination therapy for naive children with chronic hepatitis B infection
-
目的探讨拉米夫定耐药患者乙型肝炎病毒聚合酶(HBVP)基因点突变。
Objective To explore the point mutation in hepatitis B virus polymerase ( HBV P ) gene in HBV-infected patients resistant to lamivudine .
-
血清HBsAg动力学变化对慢性乙型肝炎拉米夫定治疗应答的影响
Serum HBsAg kinetics in predicting the response of chronic hepatitis B patients treated with lamivudine
-
拉米夫定耐药的HBV再感染者阿德福韦酯治疗前后HBV多聚酶基因区序列演变的研究
Evolution of HBV polymerase gene as a result of adefovir dipivoxil treatment in liver transplant patients with lamivudine resistance